Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • J&J's Janssen to pay...

    J&J's Janssen to pay $70 million to boy who developed breasts with Risperdal

    Written by savita thakur thakur Published On 2016-07-03T12:54:22+05:30  |  Updated On 3 July 2016 12:54 PM IST
    J&Js Janssen to pay $70 million to boy who developed breasts with Risperdal

    A U.S. jury awarded $70 million to the family of a boy who developed breasts after taking Johnson & Johnson unit Janssen Pharmaceuticals' antipsychotic drug Risperdal.


    The jury in the Philadelphia Court of Common Pleas found that the company failed to warn the boy's healthcare providers about the risk of gynecomastia, which is breast growth in men or boys caused by a hormonal imbalance, and that it intentionally falsified, destroyed or concealed evidence in the case, according to a copy of the verdict form provided by a spokesman for the law firm Arnold & Itkin.


    Andrew Yount, of Tennessee, developed gynecomastia at the age of five as a result of taking Risperdal, his lawyers say.


    Yount's case is one of many similar cases consolidated in the Philadelphia court. Several others have resulted in jury verdicts, but verdict dwarfs the next largest of $2.5 million.


    Other cases are also expected to go to trial, Yount's attorney, Jason Itkin, said in his statement.


    Johnson & Johnson and Janssen are facing more than 12,000 claims over Risperdal, according to Johnson & Johnson's most recent quarterly report.


    Janssen spokeswoman Kristina Chang said in an emailed statement that the verdict was "clearly excessive" and that the company would ask the court and, if necessary, an appeals court to review it.


    Risperdal was approved by the U.S. Food and Drug Administration in 2002 to treat schizophrenia, but was not cleared for use in children until 2006.


    In 2013, Johnson & Johnson and Janssen paid more than $2.2 billion to resolve civil and criminal investigations by the U.S. Department of Justice into its marketing of Risperdal and several other drugs.


    Prosecutors said that from 1999 to 2005, Janssen promoted Risperdal for uses not approved by the FDA, including behavioral disturbances in elderly people with dementia and attention deficit hyperactivity disorder and autism in children, despite knowing of its risks.

    Andrew Yountantipsychotic druggynecomastiaHealthcareJ&J'sJanssenJohnson & JohnsonKristina ChangPhiladelphia courtPhiladelphia Court of Common PleasRisperdal trialschizophreniaUS Department of JusticeUS Food & Drug AdministrationUSFDA
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok